The largest community of pharma leaders

Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that Paul Foster, M.D., senior vice president and chief medical officer at Xencor, plans to retire from Xencor effective October 31, 2019, following a transition period with a successor. Dr. Foster’s career spans 35 years in academic research, medical….

 

 

 

 

 

http://www.businesswire.com/news/home/20190627005228/en/Xencor-Announces-Planned-Retirement-Chief-Medical-Officer

Recent Articles

2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.